Grace Therapeutics Q1 EPS $(0.91) Misses $(0.18) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.18) by 405.56 percent. This is a 333.33 percent decrease over losses of $(0.21) per
Grace Therapeutics lost more money per share than experts expected—about 5 times worse. When a company loses much more than predicted, it hints that something didn't go as planned, so it's worth watching what they say about fixing it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.